Dr. Nick Galakatos is a co-founder and Managing Director of Clarus Ventures, a leading venture capital firm focused on life science investments. He has been a venture capital investor since 1992, initially at Venrock Associates and then at MPM Capital where he was General Partner of the BioVentures II and III funds. From 1997-2000 Nick was Vice President, New Business and a member of the Management Team at Millennium Pharmaceuticals. He is a co-founder Millennium Predictive Medicine and TransForm Pharmaceuticals, where he also was the Chairman and founding CEO. Nick entered the venture capital business after being Head of Molecular Biology Research at Ciba (presently Novartis). He holds a B.A degree in chemistry from Reed College, a Ph.D. degree in organic chemistry from MIT, and performed postdoctoral studies in molecular biology at Harvard Medical School.
Nick is the Lead Director at Affymax (NASDAQ: AFFY), and a member of the Board of Directors of Aerovance, Aveo, Portola and Taligen. Previously, he was the Chairman of TransForm (acquired by J&J) and Hypnion (acquired by Lilly), and a Director of Millennium Predictive Medicine (acquired by Millennium), Millennium BioTherapeutics (acquired by Millennium), Caliper (NASDAQ: CALP), Critical Therapeutics (NASDAQ: CRTX), and Syrrx (acquired by Takeda).
Nick is also a member of several Advisory Councils at Harvard Medical School, serves on the Visiting Committee for the Chemistry Department at MIT, and is a member of the Leadership Council of the Koch Institute at MIT.
Co-founder and Managing Director
Clarus Ventures
